HC Advisors’s 89bio ETNB Stock Holding History

HC Advisors’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,826	Closed	-$264K	–	94
2020 Q4	$264K	Sell	10,826 -5,533	-34%	-$141K	0.18%	69
2020 Q3	$420K	Buy	16,359 +2,959	+22%	+$93.9K	0.34%	41
2020 Q2	$267K	Buy	+13,400	New	+$326K	0.22%	67

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

HC Advisors's ETNB Position: Q1 2021 in Review

HC Advisors sold out of 89bio (ETNB) in Q1 2021, closing a stake of 10,826 shares — an estimated $264K sold.

HC Advisors first reported a position in ETNB in Q2 2020 and held it in 3 quarters. The position peaked at $420K in Q3 2020. 67 funds tracked by Wall St. Rank hold ETNB as of Q1 2021.

HC Advisors reported no remaining 89bio position as of Q1 2021 after selling out during the quarter.
HC Advisors sold 10,826 89bio shares in Q1 2021, an estimated $264K.
HC Advisors first reported a position in 89bio in Q2 2020 and held it in 3 quarters.
HC Advisors's 89bio position peaked at $420K in Q3 2020.
67 funds tracked by Wall St. Rank held 89bio as of Q1 2021.

Based on HC Advisors's 13F filing for Q1 2021, filed 7 May 2021.